Figure 1

Systemic administration of MHP1-AcN inhibited the development of IMQ-induced skin lesions and IL-17A production. MHP1-AcN (0.1, 1, 10, or 100 µg/mouse) or saline was systemically administered by daily subcutaneous injection at a distant site from IMQ application. MHP1-AcN was injected immediately before IMQ application. (A) Dorsal skin erythema and scales were recorded and measured on a four-point scale (0 = none; 1 = slight; 2 = moderate; 3 = marked; and 4 = very marked). Dorsal skin thickness was measured using a digital caliper and calculated as the percentage change from baseline. (B) Right ear thickness from day 0–8. (C) Mice were sacrificed on d8, and serum IL-17A levels were measured by ELISA. N = 3 per normal group; N = 4 per saline-treated IMQ group; N = 4 per MHP1-AcN-treated IMQ group. All values are expressed as the mean with SEM.